Cancer Biomarkers Development and Clinical Use

Monday, June 16, 2008 
at 
The Yale Club of New York City
located at
50 Vanderbilt Avenue directly across the street from Grand Central Station
between East 44th Street and East 45th Street
(one block east of Madison Avenue)
New York, New York, U.S.A. 10017

Agenda:

8:00 am – 9:00 am Registration and Continental Breakfast

9:00 am – 9:05 am Welcoming and Introductory Remarks
Joseph Dooley, Ph.D., DABCC, FACB, CEO, TriMark Publications, LLC

9:05 am – 9:45 am Keynote Speaker – Biomarkers As Prognostic Indicators Of Cancer Recurrence 
Martin Fleisher, Ph.D., Chair, Dept. of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center

9:45 am – 10:15 am Plasma-Based Assays in Hematologic Diseases: New Paradigm in Clinical Testing 
Maher Albitar, M.D., Director of Hematopathology at Nichols Institute, Quest Diagnostics, Inc.

10:15 am – 10:45 am A K-RAS Companion Diagnostic for Vectibix 
Peter Collins, Business Development Director, DxS Ltd.

10:45 am – 11:00 am Intermission – Meet the Exhibitors

11:00 am – 11:30 am How Genetics and Molecular Assays Will Change the Diagnosis and Management of Prostate Cancer
Harry Rittenhouse, Ph.D., Senior Director Cancer Program, Gen-Probe, Inc.

11:30 am – 12:00 pm Evaluation of Multiple Biomarker Assays to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass
W. Jeffrey Allard, Ph.D., Vice President, Clinical Affairs & Business Development, Fujirebio, Inc.

12:00 pm – 1:00 pm Seated Luncheon in Dining Room

1:00 pm – 1:30 pm Bringing New Cancer Assay Technologies into the Lab
Herbert Fritsche, Ph.D., Professor and Chief, Clinical Chemistry; Chairman, Scientific Advisory Board, MD Anderson Cancer Center

1:30 pm – 2:00 pm New Biomarkers for Breast Cancer Risk Stratification - H/I and MGI
Keith McCormick., Director, Sales & Marketing, AviaraDx, Inc.

2:00 pm – 2:30 pm Using Gene Expression Assays to Guide Therapy in Breast Cancer Patients
Richard Bender, M.D., FACP, Vice President and Chief Medical Officer, Agendia, Inc.

2:30 pm – 3:00 pm Development of High-Value Diagnostic Assays in Ovarian Cancer and Peripheral Arterial Disease
Eric Fung, Ph.D., Vice President and CSO, Vermillion, Inc.

3:00 pm – 3:30 pm Intermission

3:30 pm – 4:00 pm Utilizing Urinary Protein Biomarkers for Cancer Management
Anthony Shuber, Ph.D., Chief Technical Officer, Predictive Biosciences, Inc.

4:00 pm – 4:30 pm Monitoring Circulating HER-2/neu Levels In MBC Patients Treated with HER-2/neu Inhibitors
Walt Carney, Ph.D., Head, Siemens Medical Solutions Diagnostics, Oncogene Science Biomarker Group

4:30 pm – 5:00 pm Biomarkers: Discovery, Development and Clinical Applications
Kaiser J. Aziz, Ph.D., FACB, FACS, Director, KJ Biomedical Consulting, LLC

5:00 pm – 6:00 pm Reception